Trackinsight Enterprise, a unified platform for institutional ETF research, analytics, and compliance, is now live. Explore Trackinsight Enterprise →

Help us improve your experience. Please confirm your investor type:

Global ETF Survey 2026

The ETF Industry Is Evolving Fast

From AI infrastructure to active strategies, the ETF landscape is shifting. Share your perspective in the 7th Annual Global ETF Survey.

Take the survey

›ETF Issuers›State Street Investment Management›XBI

XBI

State Street SPDR S&P Biotech ETF

Passive ETF Equity

The XBI Exchange Traded Fund (ETF) is provided by State Street Investment Management. It is built to track an index: S&P Biotechnology Select Industry Index. The XBI ETF provides physical exposure, so by buying it you actually own parts of all the 146 underlying holdings. This share class generates a stream of income by distributing dividends.

$159.04

-$5.2 (-3.19%) yesterday

1:30 PM 07/10/26 Closed

1D price range

$156.27$164.24

52W price range

$85.20$164.25

YTD Perf.

+34.78%

YTD Flows

Annualized volatility

Fund AuM

€9.71B

Share class AuM

€9.71B

TTM Yield

Tracking Error

Tracking Difference

Characteristics

ISIN

US78464A8707

TER

0.35%

Inception date

1/31/2006

Issuer

State Street Investment Management

Benchmark

S&P Biotechnology Select Industry Index

Replication method

Dividend policy

Distributing

Compare similar ETFs

ETF Name	1w perf.
CURE Global X S&P Biotech ETF	+2.24%
PSCH Invesco S&P SmallCap Health Care ETF	+1.18%
AAKG ARK Genomic Revolution UCITS ETF	-0.30%
XHE State Street SPDR S&P Health Care Equipment ETF	-0.20%
XPH State Street SPDR S&P Pharmaceuticals ETF	+4.35%
BBP Virtus LifeSci Biotech Products ETF	+7.27%
XHS State Street SPDR S&P Health Care Services ETF	-1.07%
PBE Invesco Dynamic Biotechnology & Genome ETF	+0.98%
PTH Invesco DWA Healthcare Momentum ETF	+1.66%
HELX Franklin Genomic Advancements ETF	+0.34%
XLV State Street Health Care Select Sector SPDR ETF	-1.04%
VHT Vanguard Health Care ETF	-0.63%
IBB iShares Biotechnology ETF	+0.75%
FHLC Fidelity MSCI Health Care Index ETF	+1.90%
IYH iShares U.S. Healthcare ETF	-0.90%

API

PerformanceDec 31, 2025 - Jul 9, 2026

Flows

Join for free to unlock

Sector exposures

Data as of 05/31/26

Healthcare

99.41%

Unavailable

0.27%

Other

0.33%

Latest XBI news

No content available for this fund

FAQ about XBI

XBI is a Passive ETF. This ETF provides exposure to Equally Weighted US Biotechnology Equities.

XBI tracks the S&P Biotechnology Select Industry Total Return Index - USD, through a full replication replication method.

XBI carries a total expense ratio (TER) of 0.35%, indicating the annual cost for holding the fund.

XBI was introduced to the market on January 31, 2006. It trades on United States

State Street SPDR S&P Biotech ETF, XBI, is provided by State Street Investment Management. Learn more about State Street Investment Management here.

XBI oversees €9.71B in assets as of July 9, 2026.

XBI follows a distributing dividend policy, meaning it pays out income to investors. As of July 9, 2026, its 12-month trailing yield was 0.35%.

As of May 31, 2026, XBI has significant geographic allocations in USA, Ireland and Switzerland.

As of May 31, 2026, XBI focuses largely on Healthcare.

As of May 31, 2026, XBI holds 146 positions in its portfolio, with 21.98% of assets concentrated in its top 15 holdings.

As of May 31, 2026, XBI top three holdings include Travere Therapeutics, Inc., Revolution Medicines, Inc. and Alkermes Plc.

The base currency of XBI is USD.

Top 10 holdings

Data as of 05/31/26

Travere Therapeutics, Inc.

1.79%

Revolution Medicines, Inc.

1.78%

Alkermes Plc

1.71%

Twist Bioscience Corp.

1.60%

TG Therapeutics, Inc.

1.52%

Arrowhead Pharmaceuticals, Inc.

1.51%

Beam Therapeutics, Inc.

1.42%

Neurocrine Biosciences, Inc.

1.37%

Krystal Biotech, Inc.

1.36%

Exelixis, Inc.

1.36%

Essentials

A forever free toolbox for fund selection, analysis, research, and ETF portfolio construction.

Essential free account includes:

More fund data
Compare up to 3 funds
More screener filters
Edit screener columns from 100+ metrics
Watchlists for saving your research
Portfolio construction and analysis
Personal dashboard for live monitoring

About Trackinsight

Since our founding in 2016, we have been at the forefront of the industry, delivering accessible, comprehensive, and reliable tools to support the evolving needs of investors.

Over the past decade, Trackinsight has expanded its operations across six countries, serving thousands of professional investors. We’ve consistently innovated to provide cutting-edge solutions that meet the changing demands of the ETF market.

In 2024, Kepler Cheuvreux, a leading independent European financial services firm, acquired a majority stake in Trackinsight, becoming the company's principal shareholder.

This strategic partnership solidifies Trackinsight's position as a premier provider of ETF selection and analysis tools, while strengthening Kepler Cheuvreux’s commitment to becoming a leading player in the ETF sector.

Together, we are committed to offering advanced services that empower professional investors, advisors, institutions, and issuers. This new step enables us to deliver even more comprehensive and innovative technological solutions, driving ETF investing to new heights.

More about Trackinsight

The ETF Industry Is Evolving Fast

State Street SPDR S&P Biotech ETF

FAQ about XBI

Essentials

About Trackinsight

ETF TOOLS

PLATFORM

ETF NEWS & RESEARCH

PROFESSIONAL SOLUTIONS

SOLUTIONS FOR

CONTACT US